PCRX

Pacira BioSciences (PCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The latest update on Pacira BioSciences lifts the modelled fair value from US$30.00 to about US$33.57 per share, a mid single digit change that reframes where some analysts see the stock settling.

VTRS is set to acquire PCRX for $1.65 billion in cash, adding two marketed pain therapies and a clinical-stage gene therapy candidate to expand its non-opioid pain portfolio.

Viatris (VTRS) has brought renewed attention to its stock after agreeing to buy Pacira BioSciences in a US$1.65 billion all-cash deal, adding two patent-protected non-opioid pain medicines to its portfolio.

Viatris pledged Thursday to buy small biotech company Pacira Biosciences for $1.65 billion, sending Pacira stock skyrocketing.

The deal, at $36.50 per share, represents a roughly 45% premium and is expected to close by the end of 2026

Pacira BioSciences secured a $1.65 billion buyout deal with Viatris, while Haemonetics expanded its CSL Plasma partnership, prompting BTIG to raise its price target.

Viatris has agreed to acquire Pacira BioXciences, acquiring its portfolio of non-opioid pain medications.

The non-opioid pain space is attracting increasing attention as experts sound the alarm on dependency issues linked to long-term opioid-based pain management.

Viatris (VTRS) will acquire Pacira BioSciences (PCRX) in an all-cash deal worth roughly $1.65 billio